BenevolentAI is pioneering AI-driven drug discovery methods

“Can we treat chronic inflammation in ulcerative colitis by reversing immune cell activation in colonic mucosa?” That’s an example of a biological question that the AI-enabled drug discovery firm BenevolentAI (AMS:BAI) would ask when exploring a new drug target.

Incorporating a disease, sign, mechanism and tissue into a single question provides focal points for the company’s AI models to explore when generating target hypotheses, said Anne Phelan, chief scientific officer of Benevolent AI in a presentation at the Royal Society earlier this year.

BenevolentAI’s strategy involves a comprehensive understanding of the biological systems underlying various diseases, breaking down silos in clinical areas and tapping diverse multimodal data to discover novel therapeutic targets. For ulcerative colitis, the company’s AI models sift through vast amounts of scientific literature and data to spot promising targets and pathways that could potentially alleviate …

Read more
  • 0

10 pioneering companies implementing AI in drug discovery, development and beyond

[NicoElNino/Adobe Stock]

The pharma industry is embracing artificial intelligence (AI) to streamline drug discovery and development, although adoption remains early. The field, however, is rapidly expanding. The global AI in drug discovery market was worth about $1.1 billion last year but could grow at a 30% clip from 2023 to 2030, according to Grand View Research. 

In the years to come, AI could find use to discover an array of drug targets while improving drug developers’ ability to design molecules based on fine-grained criteria. Here, we spotlight several companies exploring the use of AI in drug discovery and drug development.

1. Exscientia

Oxford, UK–based Exscientia (Nasdaq: EXAI) has pioneered AI in small-molecule drug design. The company has expanded its AI-based platform to develop novel therapeutic antibodies through generative AI design. In early 2020, the company reported the first AI-d…

Read more
  • 0